IHVR-17028

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

IHVR-17028 是一种有效的广谱的抗病毒活性分子。 IHVR-17028 对 BVDV、TCRV 和 DENV 的抗病毒活性分别为 EC50 0.4 μM、0.26 μM、0.3 μM。IHVR-17028 是一种有效的ER α-葡萄糖苷酶I (α-glucosidase I) 抑制剂，其 IC50为 0.24 μM。IHVR-17028 可用于传染病研究。

IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase?I?inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research.

In virus yield reduction assays, IHVR-17028 inhibits viral activities with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM for bovine viral diarrhea virus (BVDV) (NADL strain), tacaribe virus (TCRV) (11573 strain), DENV (serotype 2, New Guinea C), respectively. And in MTT assays, IHVR-17028 exhibits IC50 values of all >500 μM inMDBK, Huh7.5 or BHK cells.

In Pharmacokinetic analysis in rats, IHVR17028 (oral gavage; 75 mg/kg) shows a Cmax?value of 0.18 μg/ml; the Tmax value is 1.56 hours; and the F% value is 12% after PO administration, the T1/2 value is 0.88 hour after iv. adminstration.IHVR-17028 (oral gavage; 25-50 mg/kg; treatment 1 day prior to virus challenging) exhibits significant protection in mouse model of lethal MARV infection.Animal Model:BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection Dosage:50 mg/kg Administration:Treatment 1 day prior to virus challenging Result:Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging.Animal Model:C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV Dosage:25 mg/kg Administration:Twice daily at 12 h interval; starting 4 h post infection for 10 days Result:Inhibited EBOV infection in mice.

——

Microbiology/Virology

Influenza Virus

Influenza Virus | Glucosidase

——

——

1428247-78-2

428.61

C23H44N2O5

>98% (HPLC)

——

C(CCCCCN(C(C(C)(C)C)=O)C1CCCCC1)N2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2

——

(-20℃)

With Ice Pack

≥ 2 years